The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Luspatercept in RBC transfusion-dependent MF patients
Aaron Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, presents updated data from the Phase II ACE-536-MF-001 study (NCT03194542) investigating luspatercept as a means of improving anemia in patients with myelofibrosis (MF) who require red blood cell (RBC) transfusions. Anemic patients often have worse outcomes and their quality of life can be greatly affected by the need for transfusions. In this study, 4 groups of patients, including those on ruxolitinib, were treated with luspatercept. The study found encouraging response rates in all groups, with durable activity of luspatercept in patients with MF-associated anemia, particularly in the transfusion-dependent responders undergoing ruxolitinib therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Aaron Gerds, MD, MS, has served on advisory boards for Galecto, PharmaEssentia and Constellation.
